Sanofi and GlaxoSmithKline are restarting clinical development of their COVID-19 vaccine, which was delayed after hitting a snag late last year.
In December interim phase 1/2 trial results showed the vaccine produced a lower immune response in older adults. The vaccine is based around an adjuvanted recombinant protein. The new phase 2 trial will involve 720 volunteers aged 18 and over to select the most appropriate antigen dosage for the next stage of development. Source: Pharmaphorum 22/2/2021